| John L Yang, MD | |
|
2014 Washington St, Newton, MA 02462-1607 | |
| (617) 219-1230 | |
| (617) 831-7350 |
| Full Name | John L Yang |
|---|---|
| Gender | Male |
| Speciality | Hematology |
| Experience | 23 Years |
| Location | 2014 Washington St, Newton, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013949551 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 219306 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Newton-wellesley Hospital | Newton, MA | Hospital |
| Massachusetts General Hospital | Boston, MA | Hospital |
| Brigham And Women's Hospital | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Newton-wellesley Medical Group, Inc. | 0244133494 | 395 |
News Archive
ST Cardio Technologies, an innovative developer of products utilized in the diagnosis and treatment of heart arrhythmias, announced today that it has been awarded a grant of $244,479 under the Qualifying Therapeutic Discovery Project (QTDP) Program. The company's grant is related to the development and clinical evaluation of the Z6 Cardiac Stimulator. The amount awarded to ST Cardio Technologies represents the maximum award for a grant under this program.
Older patients at risk of decline and death do not receive recommended medication to treat their chronic health problems about half of the time, according to a study issued by researchers from the RAND Corporation and UCLA.
Patients with a disease that is a leading cause of kidney failure tend to have high levels of a particular factor circulating in their blood, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
Up to now, it was thought that beta-blockers work directly on the heart, but the new study shows that the drugs may also act via the brain, suggesting that future therapies to treat cardiovascular disease could be targeting the central nervous system.
A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott will highlight at this year's American Association for Clinical Chemistry Lab Expo which starts today in Anaheim.
› Verified 5 days ago
| Entity Name | Massachusetts General Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801874573 PECOS PAC ID: 2466365820 Enrollment ID: O20031111000434 |
News Archive
ST Cardio Technologies, an innovative developer of products utilized in the diagnosis and treatment of heart arrhythmias, announced today that it has been awarded a grant of $244,479 under the Qualifying Therapeutic Discovery Project (QTDP) Program. The company's grant is related to the development and clinical evaluation of the Z6 Cardiac Stimulator. The amount awarded to ST Cardio Technologies represents the maximum award for a grant under this program.
Older patients at risk of decline and death do not receive recommended medication to treat their chronic health problems about half of the time, according to a study issued by researchers from the RAND Corporation and UCLA.
Patients with a disease that is a leading cause of kidney failure tend to have high levels of a particular factor circulating in their blood, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
Up to now, it was thought that beta-blockers work directly on the heart, but the new study shows that the drugs may also act via the brain, suggesting that future therapies to treat cardiovascular disease could be targeting the central nervous system.
A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott will highlight at this year's American Association for Clinical Chemistry Lab Expo which starts today in Anaheim.
› Verified 5 days ago
| Entity Name | Newton-wellesley Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538191218 PECOS PAC ID: 0244133494 Enrollment ID: O20040127001012 |
News Archive
ST Cardio Technologies, an innovative developer of products utilized in the diagnosis and treatment of heart arrhythmias, announced today that it has been awarded a grant of $244,479 under the Qualifying Therapeutic Discovery Project (QTDP) Program. The company's grant is related to the development and clinical evaluation of the Z6 Cardiac Stimulator. The amount awarded to ST Cardio Technologies represents the maximum award for a grant under this program.
Older patients at risk of decline and death do not receive recommended medication to treat their chronic health problems about half of the time, according to a study issued by researchers from the RAND Corporation and UCLA.
Patients with a disease that is a leading cause of kidney failure tend to have high levels of a particular factor circulating in their blood, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
Up to now, it was thought that beta-blockers work directly on the heart, but the new study shows that the drugs may also act via the brain, suggesting that future therapies to treat cardiovascular disease could be targeting the central nervous system.
A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott will highlight at this year's American Association for Clinical Chemistry Lab Expo which starts today in Anaheim.
› Verified 5 days ago
| Entity Name | The General Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023049236 PECOS PAC ID: 6507803806 Enrollment ID: O20080313000351 |
News Archive
ST Cardio Technologies, an innovative developer of products utilized in the diagnosis and treatment of heart arrhythmias, announced today that it has been awarded a grant of $244,479 under the Qualifying Therapeutic Discovery Project (QTDP) Program. The company's grant is related to the development and clinical evaluation of the Z6 Cardiac Stimulator. The amount awarded to ST Cardio Technologies represents the maximum award for a grant under this program.
Older patients at risk of decline and death do not receive recommended medication to treat their chronic health problems about half of the time, according to a study issued by researchers from the RAND Corporation and UCLA.
Patients with a disease that is a leading cause of kidney failure tend to have high levels of a particular factor circulating in their blood, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
Up to now, it was thought that beta-blockers work directly on the heart, but the new study shows that the drugs may also act via the brain, suggesting that future therapies to treat cardiovascular disease could be targeting the central nervous system.
A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott will highlight at this year's American Association for Clinical Chemistry Lab Expo which starts today in Anaheim.
› Verified 5 days ago
| Entity Name | Steward St. Annes Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932411493 PECOS PAC ID: 3678760493 Enrollment ID: O20101206001124 |
News Archive
ST Cardio Technologies, an innovative developer of products utilized in the diagnosis and treatment of heart arrhythmias, announced today that it has been awarded a grant of $244,479 under the Qualifying Therapeutic Discovery Project (QTDP) Program. The company's grant is related to the development and clinical evaluation of the Z6 Cardiac Stimulator. The amount awarded to ST Cardio Technologies represents the maximum award for a grant under this program.
Older patients at risk of decline and death do not receive recommended medication to treat their chronic health problems about half of the time, according to a study issued by researchers from the RAND Corporation and UCLA.
Patients with a disease that is a leading cause of kidney failure tend to have high levels of a particular factor circulating in their blood, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
Up to now, it was thought that beta-blockers work directly on the heart, but the new study shows that the drugs may also act via the brain, suggesting that future therapies to treat cardiovascular disease could be targeting the central nervous system.
A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott will highlight at this year's American Association for Clinical Chemistry Lab Expo which starts today in Anaheim.
› Verified 5 days ago
| Entity Name | Steward St. Annes Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1295027134 PECOS PAC ID: 3678760493 Enrollment ID: O20110912000586 |
News Archive
ST Cardio Technologies, an innovative developer of products utilized in the diagnosis and treatment of heart arrhythmias, announced today that it has been awarded a grant of $244,479 under the Qualifying Therapeutic Discovery Project (QTDP) Program. The company's grant is related to the development and clinical evaluation of the Z6 Cardiac Stimulator. The amount awarded to ST Cardio Technologies represents the maximum award for a grant under this program.
Older patients at risk of decline and death do not receive recommended medication to treat their chronic health problems about half of the time, according to a study issued by researchers from the RAND Corporation and UCLA.
Patients with a disease that is a leading cause of kidney failure tend to have high levels of a particular factor circulating in their blood, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
Up to now, it was thought that beta-blockers work directly on the heart, but the new study shows that the drugs may also act via the brain, suggesting that future therapies to treat cardiovascular disease could be targeting the central nervous system.
A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott will highlight at this year's American Association for Clinical Chemistry Lab Expo which starts today in Anaheim.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John L Yang, MD 62 Birch Ln, Westwood, MA 02090-1530 Ph: (508) 235-5226 | John L Yang, MD 2014 Washington St, Newton, MA 02462-1607 Ph: (617) 219-1230 |
News Archive
ST Cardio Technologies, an innovative developer of products utilized in the diagnosis and treatment of heart arrhythmias, announced today that it has been awarded a grant of $244,479 under the Qualifying Therapeutic Discovery Project (QTDP) Program. The company's grant is related to the development and clinical evaluation of the Z6 Cardiac Stimulator. The amount awarded to ST Cardio Technologies represents the maximum award for a grant under this program.
Older patients at risk of decline and death do not receive recommended medication to treat their chronic health problems about half of the time, according to a study issued by researchers from the RAND Corporation and UCLA.
Patients with a disease that is a leading cause of kidney failure tend to have high levels of a particular factor circulating in their blood, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
Up to now, it was thought that beta-blockers work directly on the heart, but the new study shows that the drugs may also act via the brain, suggesting that future therapies to treat cardiovascular disease could be targeting the central nervous system.
A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott will highlight at this year's American Association for Clinical Chemistry Lab Expo which starts today in Anaheim.
› Verified 5 days ago
John D Freedman, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 29 Crafts St, Suite 470, Newton, MA 02458 Phone: 617-243-9509 | |
Ms. Marta Christov, MD, PHD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2000 Washington St Ste 460, Newton, MA 02462 Phone: 617-243-5420 | |
Caroline Stowell, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 2014 Washington St, Medical Education, Newton, MA 02462 Phone: 617-243-6467 Fax: 617-243-6701 | |
Dr. Harley Anne Simeone, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 272 Centre St, Newton, MA 02458 Phone: 617-796-7170 Fax: 617-796-7171 | |
Meghan E Gange, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2014 Washington St, Newton, MA 02462 Phone: 617-243-6345 | |
Dr. Arthur Robert Kennedy Jr., M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 2014 Washington St, Department Of Hospital Medicine, Newton, MA 02462 Phone: 617-243-6433 |